Pts with advanced head and neck squamous cell carcinoma failing prior therapies and those unsuitable for surgery

Adverse effects include pain, haemorrhage pain in face, injection site pain, scar, Mouth necrosis, dysphagia, face oedema, Constipation, vomiting, Anemia, trismus, loaclised infection, Fever, hyperpigmentation, Photosensitivity reaction & skin necrosis.

Prophyrias, Tumors known to be eroding into a major blood vessel in or adjacent to the illumination site

Planned surgical procedure within the next 30 days. coexisting ophthalmic diseases likely to require slit-lsamp examination within the next 30 days

Existing therapy with a photoosensitizing agent, pregnanct (first trimester)

Precautions-

Special care must be taken to prevent extravasation at injection site. If extrvastion ocurs protect the are from Light for at least 3 months, lactation.

Pts with advanced head and neck squamous cell carcinoma failing prior therapies and those unsuitable for surgery

Dosage-

Administered at dosage of 0.15mg/kg and administered as a single slow intravenous injection.

Pharmacology-

Temoporofin like most photosensitizers binds to cellular membranes after intervenous adimintration & enters the cellular intestinal space. Mechanism of action- The anti-tumor activity of temporfin depends on photoactivation with light of 652 nm from a laser. The molecular basis of photosensitivity & photodynamic effects is fairly well understood. Absorption of photons by temoporfin results in the promotion of electrons to higher energy states

Contraindicated during first trimester of pregnancy.